These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30701029)

  • 21. Resveratrol induces apoptosis and autophagy in T-cell acute lymphoblastic leukemia cells by inhibiting Akt/mTOR and activating p38-MAPK.
    Ge J; Liu Y; Li Q; Guo X; Gu L; Ma ZG; Zhu YP
    Biomed Environ Sci; 2013 Nov; 26(11):902-11. PubMed ID: 24331535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells.
    Barata JT; Silva A; Brandao JG; Nadler LM; Cardoso AA; Boussiotis VA
    J Exp Med; 2004 Sep; 200(5):659-69. PubMed ID: 15353558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calcineurin complex isolated from T-cell acute lymphoblastic leukemia (T-ALL) cells identifies new signaling pathways including mTOR/AKT/S6K whose inhibition synergize with calcineurin inhibition to promote T-ALL cell death.
    Tosello V; Saccomani V; Yu J; Bordin F; Amadori A; Piovan E
    Oncotarget; 2016 Jul; 7(29):45715-45729. PubMed ID: 27304189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K; Douglas L; Delaney A; Houghton JA
    Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma.
    Dreyling MH; Bullinger L; Ott G; Stilgenbauer S; Müller-Hermelink HK; Bentz M; Hiddemann W; Döhner H
    Cancer Res; 1997 Oct; 57(20):4608-14. PubMed ID: 9377576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways.
    Piazza F; Manni S; Ruzzene M; Pinna LA; Gurrieri C; Semenzato G
    Leukemia; 2012 Jun; 26(6):1174-9. PubMed ID: 22289987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal interleukin-7 receptor-mediated signaling, cell cycle progression and viability of T-cell acute lymphoblastic leukemia cells rely on casein kinase 2 activity.
    Melão A; Spit M; Cardoso BA; Barata JT
    Haematologica; 2016 Nov; 101(11):1368-1379. PubMed ID: 27470599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
    Mendes RD; Canté-Barrett K; Pieters R; Meijerink JP
    Haematologica; 2016 Sep; 101(9):1010-7. PubMed ID: 27582570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
    Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
    Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.
    Cani A; Simioni C; Martelli AM; Zauli G; Tabellini G; Ultimo S; McCubrey JA; Capitani S; Neri LM
    Oncotarget; 2015 Mar; 6(9):6597-610. PubMed ID: 25788264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
    Hall CP; Reynolds CP; Kang MH
    Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
    Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
    J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
    Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
    Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt/mammalian target of rapamycin and extracellular signal-related kinase signaling pathways.
    Wu KN; Zhao YM; He Y; Wang BS; Du KL; Fu S; Hu KM; Zhang LF; Liu LZ; Hu YX; Wang YJ; Huang H
    Leuk Lymphoma; 2014 Mar; 55(3):668-76. PubMed ID: 23741975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
    Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
    Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Limited redundancy in phosphorylation of retinoblastoma tumor suppressor protein by cyclin-dependent kinases in acute lymphoblastic leukemia.
    Schmitz NM; Hirt A; Aebi M; Leibundgut K
    Am J Pathol; 2006 Sep; 169(3):1074-9. PubMed ID: 16936279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia.
    Quotti Tubi L; Canovas Nunes S; Brancalion A; Doriguzzi Breatta E; Manni S; Mandato E; Zaffino F; Macaccaro P; Carrino M; Gianesin K; Trentin L; Binotto G; Zambello R; Semenzato G; Gurrieri C; Piazza F
    Leukemia; 2017 Feb; 31(2):292-300. PubMed ID: 27479180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Novel Aziridine-based Bruton's Tyrosine Kinase Inhibitor Induces Apoptosis Through Down-regulation of p65/RelA Phosphorylation on Serine 536 and ERK1/2 in Mantle Cell Lymphoma.
    Romanchikova N; Strods A; Strazdina J; Strumfs B; Trapencieris P
    Anticancer Res; 2016 Nov; 36(11):6133-6140. PubMed ID: 27793942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phosphoinositide-dependent protein kinase 1 is a potential novel therapeutic target in mantle cell lymphoma.
    Maegawa S; Chinen Y; Shimura Y; Tanba K; Takimoto T; Mizuno Y; Matsumura-Kimoto Y; Kuwahara-Ota S; Tsukamoto T; Kobayashi T; Horiike S; Taniwaki M; Kuroda J
    Exp Hematol; 2018 Mar; 59():72-81.e2. PubMed ID: 29287939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Butein inhibits NF-κB, AP-1 and Akt activation in adult T-cell leukemia/lymphoma.
    Ishikawa C; Senba M; Mori N
    Int J Oncol; 2017 Aug; 51(2):633-643. PubMed ID: 28586006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.